ERIVEDGE gél 150 mg 28 pce

7680624970014 CH-62497 L01XJ01 07.16.4.

Reimbursement limitations:

ERIVEDGE2

ERIVEDGE est indiqué dans le traitement des patients adultes atteints d’un carcinome basocellulaire avancé chez …

ERIVEDGE gél 150 mg 28 pce
ERIVEDGE gél 150 mg 28 pce
ERIVEDGE gél 150 mg 28 pce
1 / 3
google

Details

Product number
6249701
CPT
-
Packaging group
28
Unit
Kapsel(n)
Composition
vismodegibum 150 mg, cellulosum microcristallinum, lactosum monohydricum 71.5 mg, natrii laurilsulfas, povidonum K 29-32, carboxymethylamylum natricum, talcum, magnesii stearas, Kapselhülle: gelatina, E 171, E 172 (rubrum), E 172 (nigrum), Drucktinte: lacca, E 172 (nigrum), excipiens pro capsula corresp. natrium 1.09 - 1.34 mg.

Articles (1)

Erivedge, Kapseln
Kapseln
28
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
05/07/2023
Patient information leaflet
Français
05/07/2023
Patient information leaflet
Italien
05/07/2023
Professional SmPC
Allemand
05/07/2023
Professional SmPC
Français
05/07/2023
Professional SmPC
Italien
05/07/2023

Detailed composition

Substance Quantity Type Category
(N/A)
150.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
71.5 MG Substance HBESI
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FNIDK
(N/A)
- Substance FTODK
(N/A)
- Substance FTODK
(N/A)
- Substance HNIDK
(N/A)
- Substance FTODK
(N/A)
- Substance HBESI

Reimbursement information

Public price
CHF 5317.00
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/10/2013

Authorization holder

Roche Pharma (Schweiz) AG

4058 Basel

Authorization information

Swissmedic authorization number
62497
Drug name
Erivedge, Kapseln
Galenic form
KAHA
ATC Code
L01XJ01
Authorization status
Z
Dispensation category
A
First authorization
30/05/2013
Authorization expiration date
31/12/9999
IT number
07.16.4.
Domain
Human medicine
Field of application
Zytostatikum

Packaging details

Description (FR)
ERIVEDGE gél 150 mg 28 pce
Description (DE)
ERIVEDGE Kaps 150 mg 28 Stk
Market launch
30/05/2013
Narcotic (BTM)
No